바로가기
메인메뉴로 바로가기
콘텐츠 바로가기
하단메뉴로 바로가기
패밀리사이트 바로가기


진료과

  • 연세암병원-종양내과, 위암센터

전문진료분야

  • <종양내과> 위암, 육종, 항암약물치료, 신약치료

진료시간표

인터넷진료예약
의사시간표
진료시간
오전 암병원 암병원
오후 암병원 암병원

교육 및 임상 경력

  • 2002.3-2003.2  삼성서울병원  인턴  (의사)
  • 2004.3-2008.2  삼성서울병원  내과  전공의  (내과  전문의) 
  • 2007.7-2007.8  Singapore  National  Cancer  Center  단기  연수
  • 2008.3-2009.2  삼성서울병원  혈액종양학과  전임의
  • 2009.3-2010.2  연세의대  내과학교실  임상연구  조교수
  • 2010.3-2017.2  연세의대  내과학교실  임상조교수
  • 2017.3-현재          연세의대  내과학교실  조교수

학술관련경력

  • 2007.12 삼성서울병원 내과학 교실 - 전공의 우수 논문상
  • 2008.12.31. 젊은 연구자상 수상 (Korean Association for Clinical Oncology)
  • 2009. 3 보건의료 기술연구개발사업 임상의과학자 양성 연구자 선정
  • 2009. 5 연세대학교 내과 학술 연구자 선정
  • 2009. 6 대한암학회 GSK 최우수 연제수상
  • 2009.11 아시아태평양 암학회 젊은 연구자상
  • 2009.11 임상암학회 암전문가 교육사업 수상자
  • 2010.6 LG 미래 의학자상 수상
  • 2011.4 젊은 연구자상 수상. 제 9 회 세계 위암학회
  • 2011.6 Roche 우수 논문상 (Korean Cancer Society)
  • <학회 활동>
  • 대한암학회 회원
  • 대한내과학회 회원
  • 임상암학회 회원
  • 항암요법연구회 회원
  • 대한 혈액학회 회원

주요 관심분야

  • 항암약물치료: 위암, 식도암, 육종, 희귀암
  • 종양생물학

학력사항

  • 1996.3-2002.2 국립경상대학교 의과대학
  • 2002.3-2007.2 삼성서울병원 내과 전공의 (내과 전문의)
  • 2008.3-2009.2 삼성서울병원 혈액종양학과 임상강사
  • 2006.3-2008.2 성균관대학교 대학원 석사
  • 2009.3-2013.8 성균관대학교 대학원 박사

논문

  • 1.Kim HS, Park YH, Park MJ, Chang MH, Jun HJ, Kim KH, Ahn JS, Kang WK, Park K, Im YH.. Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer. Breast Cancer Res Treat. 2009 Mar 26
  • 2.Kim HS, Kim KH, Kim KH, Chang MH, Ji SH, Lim DH, Kim K, Kim SJ, Ko Y, Ki CS, Jo SJ, Lee JW, Kim WS. Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. Leuk Lymphoma. 2009 Mar 27:1-7
  • 3.Kim HS, Yi SY, Jun HJ, Lee J, Park JO, Park YS, Jang J, Kim HJ, Ko Y, Lim HY, Kang WK. Clinical Outcome of Gastric Cancer Patients with Bone Marrow Metastases
  • Oncology. 2008 April 16, 73:192-7.
  • 4.HS Kim, K Park, HJ Jun, SY Yi, J Lee, JS Ahn, YH Park, S Kim, Sl Lee, MJ Ahn
  • Comparison of survival between the pre- and post-gefitinib eras for advanced non-small cell lung cancer patients. Oncology. 2009 Feb 25;76(4):239-246
  • 5.HS Kim, WS Kim, CW Jung, HY Choi, HM Lee, SS Jeon, H Ha. IG Hwang, S Lee, HY Lim. Molecular Biomarker for Advanced Renal Cell Carcinoma. Urologic Oncology. 2008 Oct 29 [Epub ahead of print]
  • 6.Kim HS, Yi SY, Jun HJ, Ahn JS, Ahn MJ, Lee J, Kim Y, Cui ZY, Hong HJ, Kim JM, Li S, Hwang IG, Park K. L1 cell adhesion molecule as a predictor for recurrence in pulmonary carcinoids and large-cell neuroendocrine tumors. APMIS. 2009 Feb;117(2):140-6.
  • 7.Hyo Song Kim, Youngwook Kim, Zheng Yun Cui, Hye-sook Lee,Jin Seok Ahn, Chan Keum Park, Keunchil Park and Myung-ju Ahn. Clinicopathological Implications of EpCAM Expression in Adenocarcinoma of the Lung. ANTICANCER RESEARCH. 2009.Vol 29
  • 8.Kim HS, Chang WI, Kim YC, Yi SY, Kil JS, Hahn JY, Kang M, Lee MS, Lee SH. Catecholamine cardiomyopathy associated with paraganglioma rescued by percutaneous cardiopulmonary support: inverted Takotsubo contractile pattern. Circ J. 2007 Dec;71(12):1993-5.
  • 9.HS Kim, HJ Jun, HW Chang, HK Choi, SY Yi, GY Kwon, WS Kim. A case of leukemoid reaction in a patient with advanced transitional cell carcinoma. Korean Journal of Medicine 2006 , Vol 71,
  • 10.Jun HJ, Ahn MJ, Kim HS, Yi SY, Han J, Lee SK, Ahn YC, Jeong HS, Son YI, Baek JH, Park K.. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer. 2008 Jul 8; 167-172
  • 11.Yi SY, Park YS, Kim HS, Jun HJ, Kim KH, Chang MH, Park MJ, Uhm JE, Lee J, Park SH, Park JO, Lee JK, Lee KT, Lim HY, Kang WK. Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer. Cancer Chemother Pharmacol 2008 Oct 7;
  • 12.Kim KH, Park YS, Chang MH, Kim HS, Jun HJ, Uhm J, Yi SY, Lim DH, Ji SH, Park MJ, Lee J, Park SH, Park JO, Lim HY, Kang WK. A phase I/II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer.
  • Cancer Chemother Pharmacol. 2008 Dec 6
  • 13.Lee J, Im YH, Cho EY, Hong YS, Lee HR, Kim HS, Kim MJ, Kim K, Kang WK, Park K, Shim YM. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. Cancer Chemother Pharmacol 2008 Jun 62(1): 77-84
  • 14.Chang MH, Kim KH, Jun HJ, Kim HS, Yi SY, Uhm JE, Park MJ, Lim DH, Ji SH, Hwang IG, Lee J, Park YH, Ahn JS, Ahn MJ, Park K. Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung Cancer Cancer Chemother Pharmacol. 2009 Feb 17.
  • 15.Ji SH, Lim DH, Yi SY, Kim HS, Jun HJ, Kim KH, Chang MH, Park MJ, Uhm JE, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK. A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer. BMC Cancer. 2009 Apr 9;9(1):110
  • 16.Yang JH, Park SW, Yang JH, Cho SW, Kim HS, Choi KA, Kim HJ. Dynamic left ventricular outflow tract obstruction without basal septal hypertrophy, caused by catecholamine therapy and volume depletion. Korean J Intern Med. 2008 Jun;23(2):106-9.
  • 17.Chang
  • Catecholamine cardiomyopathy associated with paraganglioma rescued by percutaneous cardiopulmonary support - Inverted takotsubo contractile pattern
    CIRCULATION JOURNAL 71/12 :1993-1995,2007
  • Clinical outcome of gastric cancer patients with bone marrow metastases
    ONCOLOGY 73/3-4 :192-197,2007
  • A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma
    Cancer Chemotherapy And Pharmacology 62/1 :77-84,2008
  • ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation
    British Journal Of Cancer 99/1 :167-172,2008
  • Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in korea
    Cancer Research And Treatment 41/2 :67-72,2009
  • Liposarcoma: exploration of clinical prognostic factors for risk based stratification of therapy
    Bmc Cancer 9/205 :-,2009
  • Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 64/5 :917-924,2009
  • Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer
    Journal Of Thoracic Oncology 4/7 :809-815,2009
  • A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer
    Bmc Cancer 9/110 :1-6,2009
  • L1 cell adhesion molecule as a predictor for recurrence in pulmonary carcinoids and large-cell neuroendocrine tumors
    Apmis 117/2 :140-146,2009
  • Clinicopathological Implications of EpCAM Expression in Adenocarcinoma of the Lung
    Anticancer Research 29/5 :1817-1822,2009
  • Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma
    Leukemia & Lymphoma 50/5 :757-763,2009
  • Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer
    Breast Cancer Research And Treatment 118/1 :89-97,2009
  • Comparison of Survival in Advanced Non-Small Cell Lung Cancer Patients in the Pre- and Post-Gefitinib Eras
    Oncology 76/4 :239-246,2009
  • Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 63/6 :1141-1145,2009
  • The Clinical Outcome of Chemotherapy-Induced Amenorrhea in Premenopausal Young Patients with Breast Cancer with Long-Term Follow-up
    Annals of Surgical Oncology 17/12 :3259-3268,2010
  • Novel Sunitinib Strategy in Metastatic Renal Cell Carcinoma on Hemodialysis: Intermittent Dose of Sunitinib after Hemodialysis
    Cancer Research and Treatment 42/3 :180-184,2010
  • Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer
    Anti-Cancer Drugs 21/1 :107-112,2010
  • Clinicopathologic Features of Metachronous or Synchronous Gastric Cancer Patients with Three or More Primary Sites
    Cancer Research and Treatment 42/4 :217-224,2010
  • Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter study
    Bmc Cancer 10/167 :-,2010
  • Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy
    Apmis 118/ :941-948,2010
  • Molecular biomarkers for advanced renal cell carcinoma: Implications for prognosis and therapy
    Urologic Oncology-Seminars And Original Investigations 28/2 :157-163,2010
  • A Prognostic Model to Predict Clinical Outcome in Gastric Cancer Patients with Bone Metastasis
    ONCOLOGY 80/1-2 :142-150,2011
  • Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity Profiles
    ONCOLOGY 80/5-6 :395-405,2011
  • Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 68/0 :991-999,2011
  • Advanced Detection of Recent Changing Trends in Gastric Cancer Survival: Up-to-date Comparison by Period Analysis
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY 41/ :1344-1350,2011
  • A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer
    EUROPEAN JOURNAL OF CANCER 48/ :518-526,2012
  • External validation of nomogram for the prediction of recurrence after curative resection in early gastric cancer
    ANNALS OF ONCOLOGY 23/ :361-U336,2012
  • Weekly Gemcitabine and Docetaxel in Refractory Soft Tissue Sarcoma: A Retrospective Analysis
    Cancer Research and Treatment 44/1 :43-49,2012
  • The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 70/4 :539-546,2012
  • Therapeutic Strategies for Well-differentiated Papillary Mesothelioma of the Peritoneum.
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY 43/10 :996-1003,2013
  • Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors
    SUPPORTIVE CARE IN CANCER 21/6 :1751-1759,2013
  • Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 72/ :825-835,2013
  • Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 72/4 :853-860,2013
  • Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study
    JOURNAL OF CLINICAL PATHOLOGY 67/1 :33-39,2014
  • Vascular Soft-Tissue Sarcomas: A Prognostic Model from a Retrospective Single-Center Study
    ONCOLOGY 86/5-6 :329-335,2014
  • Ifosfamide-induced Fanconi syndrome with diabetes insipidus
    KOREAN JOURNAL OF INTERNAL MEDICINE 29/2 :246-249,2014
  • Clinical Features and Treatment of Collecting Duct Carcinoma of the Kidney from the Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee
    CANCER RESEARCH AND TREATMENT 46/2 :141-147,2014
  • PTEN Deficiency as a Predictive Biomarker of Resistance to HER2-Targeted Therapy in Advanced Gastric Cancer
    ONCOLOGY 88/2 :76-85,2015
  • Proper Timing of Adjuvant Chemotherapy Affects Survival in Patients with Stage 2 and 3 Gastric Cancer
    ANNALS OF SURGICAL ONCOLOGY 22/1 :224-231,2015
  • Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children
    CANCER RESEARCH AND TREATMENT 47/1 :9-17,2015
  • Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma
    ONCOTARGET 6/4 :2562-2572,2015
  • The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer
    LUNG CANCER 88/3 :325-331,2015
  • Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: A retrospective case series
    BMC CANCER 15/154 :1-7,2015
  • Clinicopathological Features and Prognostic Significance of HER2 Expression in Gastric Cancer
    ONCOLOGY 88/3 :147-156,2015
  • Leiomyosarcoma: investigation of prognostic factors for risk-stratification model
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY 20/6 :1226-1232,2015
  • Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine
    CANCER RESEARCH AND TREATMENT 74/4 :781-789,2015
  • Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma
    ONCOTARGET 6/42 :44971-44984,2015
  • 골종양의 항암치료에 대한 전략
    대한정형외과학회지 50/6 :438-443,2015
  • Multidisciplinary treatment of inferior vena cava leiomyosarcoma.
    ANZ JOURNAL OF SURGERY 86/1-2 :104-105,2016
  • Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy
    ANNALS OF SURGERY 263/1 :96-102,2016
  • Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites
    ONCOTARGET 7/7 :8055-8066,2016
  • Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional Experience.
    JOURNAL OF CANCER 7/9 :1174-1180,2016
  • Prognostic implications of PIK3CA amplification in curatively resected liposarcoma
    ONCOTARGET 7/17 :24549-24558,2016
  • PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma
    ONCOTARGET 7/21 :30691-30701,2016
  • Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma
    ANNALS OF NUCLEAR MEDICINE 30/4 :279-286,2016
  • Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma.
    BMC CANCER 16/434 :1-7,2016
  • Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: Implications for individualized therapy
    ONCOTARGET 7/28 :44608-44620,2016
  • Prognostic significance and frequency of EGFR expression and amplification in surgically resected advanced gastric cancer
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY 46/6 :507-516,2016
  • A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology
    CANCER RESEARCH AND TREATMENT 48/2 :553-560,2016
  • Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus
    ONCOTARGET 7/9 :10,547-10,556,2016
  • Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08.
    CANCER RESEARCH AND TREATMENT 48/4 :1,286-1,292,2016
  • Recursive Partition Analysis of Peritoneal and Systemic Recurrence in Patients With Gastric Cancer Who Underwent D2 Gastrectomy: Implications for Neoadjuvant Therapy Consideration
    JOURNAL OF SURGICAL ONCOLOGY 114/7 :859-864,2016
  • Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm
    ONCOTARGET 7/44 :72,099-72,112,2016
  • A novel TP53-KPNA3 translocation defines a de novo treatment-resistant clone in osteosarcoma
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE 2/5 :a000992-,2016
  • Different subtypes of epithelioid sarcoma and their clinical implication: long-term multi-institutional experience with a rare sarcoma
    APMIS 125/3 :223-229,2017
  • Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab.
    ONCOTARGET 8/19 :31,169-31,179,2017
  • Reassessment of alkaline phosphatase as serum tumor marker with high specificity in osteosarcoma
    CANCER MEDICINE 6/6 :1,311-1,322,2017
  • Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer
    ONCOTARGET 8/24 :38,389-38,398,2017
  • Locoregional relapse after gastrectomy with D2 lymphadenectomy for gastric cancer
    BRITISH JOURNAL OF SURGERY 104/7 :877-884,2017
  • Outcomes of Treatment for Malignant Peripheral Nerve Sheath Tumors: Different Clinical Features Associated with Neurofibromatosis Type 1
    CANCER RESEARCH AND TREATMENT 49/3 :717-726,2017
  • Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
    ONCOTARGET 8/37 :61,837-61,845,2017
  • Integration of radiotherapy and chemotherapy for abdominal lymph node recurrence in gastric cancer
    CLINICAL & TRANSLATIONAL ONCOLOGY 19/10 :1,268-1,275,2017
  • Patterns of Care for Radiotherapy in the Neoadjuvant and Adjuvant Treatment of Gastric Cancer: A Twelve-Year Nationwide Cohort Study in Korea
    CANCER RESEARCH AND TREATMENT 50/1 :118-128,2018
  • Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma.
    BMC CANCER 18/1 :158-165,2018
  • Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee.
    KOREAN JOURNAL OF INTERNAL MEDICINE 33/2 :383-390,2018
  • The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status
    GASTRIC CANCER 21/2 :213-224,2018
  • Prognostic significance of preoperative CT findings in patients with advanced gastric cancer who underwent curative gastrectomy
    PLOS ONE 13/8 :e0202207-e0202220,2018
  • A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy
    AAPS JOURNAL 20/4 :72-87,2018
  • Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial.
    ANNALS OF SURGICAL ONCOLOGY 25/11 :3,222-3,230,2018
  • Efficacy of Postoperative Radiotherapy Using Modern Techniques in Patients with Retroperitoneal Soft Tissue Sarcoma
    YONSEI MEDICAL JOURNAL 59/9 :1,049-1,056,2018
  • Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial.
    CLINICAL CANCER RESEARCH 24/21 :5,272-5,281,2018
  • Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy
    BMC CANCER 18/1 :1116-1127,2018
  • S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial
    CANCER RESEARCH AND TREATMENT 51/1 :1-11,2019
  • Clinical analysis of patients with skeletal metastasis of lung cancer.
    BMC CANCER 19/1 :303-303,2019
  • Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer
    RADIOTHERAPY AND ONCOLOGY 140/ :143-149,2019
  • Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial
    CANCER RESEARCH AND TREATMENT 51/2 :819-831,2019
  • Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma.
    ONCOLOGY 96/2 :59-69,2019
  • Characteristics and Treatment Patterns of Patients with Advanced Soft Tissue Sarcoma in Korea
    CANCER RESEARCH AND TREATMENT 51/4 :1,380-1,391,2019
  • Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer
    Journal for ImmunoTherapy of Cancer 7/1 :e268-,2019
  • Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer
    GASTRIC CANCER 22/6 :1,153-1,163,2019
  • Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer.
    EUROPEAN JOURNAL OF CANCER 112/ :20-28,2019

김효송

콘텐츠 처음으로 이동

네크워크 링크안내/사이트 정보